Results 71 to 80 of about 27,755 (279)

GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. [PDF]

PLoS ONE, 2012
Glucose-dependent insulinotropic polypeptide (GIP) is a gastrointestinal hormone that potentiates glucose-stimulated insulin secretion during a meal. Since GIP has also been shown to exert β-cell prosurvival and adipocyte lipogenic effects in rodents ...
Su-Jin Kim, Cuilan Nian, Subashini Karunakaran, Susanne M Clee, Carlos M Isales, Christopher H S McIntosh   +5 more
doaj   +1 more source

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

Central GIP signaling stimulates peripheral GIP release and promotes insulin and pancreatic polypeptide secretion in nonhuman primates

, 2016
Glucosedependent insulinotropic polypeptide (GIP) has important actions on whole body metabolic function. GIP and its receptor are also present in the central nervous system and have been linked to neurotrophic actions.
Tejero, M. Elizabeth, I. P. Rodríguez Sánchez, P. B. Higgins, S. A. Cole, M. Garcia Forey, M. . E. Tejero, Voruganti, V. Saroja, F. Folli, R. E. Shade, Rodríguez-Sánchez, Irám P., V. . S. Voruganti, Comuzzie, Anthony G., Higgins, Paul B., Shade, Robert E., Cole, Shelley A., A. G. Comuzzie, Folli, Franco, Garcia-Forey, Magdalena   +17 more
core   +2 more sources

The postprandial dynamics of gastroduodenal zone hormones in patients with metabolic obesity associated or not associated with type 2 diabetes

Сахарный диабет, 2015
Background. The main aims of the conservative treatment of metabolic obesity (MО) are weight loss and the prevention of type 2 diabetes. Incretin-based drugs are considered to be effective and safe and stimulate insulin secretion via the β-cells of the ...
Elena Vital'evna Kirienkova, Mariia Aleksandrovna Vasilenko, Pavel Anatol'evich Zatolokin, Nataliya Ivanovna Mironyuk, Dar'ya Aleksandrovna Skuratovskaia, Larisa Sergeevna Litvinova   +5 more
doaj   +1 more source

Gip, an Intestinal Metabolic Hormone.

, 2020
Using an established radioimmunoassay for immunoreactive gastric inhibitory polypeptide (IR-GIP) the metabolic actions of gastric inhibitory polypeptide (GIP) were investigated.
Kwasowski, Piotr.
core  

Endoscopic small bowel therapies for type 2 diabetes

Nutrition in Clinical Practice, EarlyView.
Abstract Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux‐en‐Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the ...
Roma Patel, Zehra Naseem, Prisha Gattu, Stephen Firkins, Roberto Simons‐Linares   +4 more
wiley   +1 more source

Stimulating intestinal GIP release reduces food intake and body weight in mice

Molecular Metabolism
Objective: Glucose dependent insulinotropic polypeptide (GIP) is well established as an incretin hormone, boosting glucose-dependent insulin secretion.
Jo E. Lewis, Danae Nuzzaci, Paula-Peace James-Okoro, Mireia Montaner, Elisabeth O'Flaherty, Tamana Darwish, Marito Hayashi, Stephen D. Liberles, David Hornigold, Jacqueline Naylor, David Baker, Fiona M. Gribble, Frank Reimann   +12 more
doaj   +1 more source

Market potential and productivity: Evidence from Finnish regions

, 2006
New economic geography (NEG) stresses the role of various types of linkages as agglomeration forces. We show that a typical NEG model can be used to design an empirical methodology to assess whether linkages are relevant at all and, if so, whether they ...
Ottaviano, GIP, Pinelli, D
core   +1 more source

SURMOUNT‐REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity

Obesity, EarlyView.
ABSTRACT Objective SURMOUNT‐REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard‐of‐care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m2) and without diabetes in a UK primary care setting. Methods A 5‐year, phase 4, multicenter, open‐label, pragmatic randomized clinical trial is enabled through ...
Martin K. Rutter, Julie Mount, J. Martin Gibson, Joanne Webb, Cheryl Marler, Catherine Reed, Mugdha Gore, Wenyu Ye, Elisa Gomez Valderas, John Wilding, Naveed Sattar, Melanie J. Davies, Kamlesh Khunti, Richard Haynes, Rachel L. Batterham   +14 more
wiley   +1 more source

Incretin-based therapies for cardio-kidney-liver-metabolic disease: the role of the liver in the modern era of chronic disease management [PDF]

Clinical and Molecular Hepatology
Steatotic liver disease (SLD) is a leading cause of disease globally and demands new therapeutic approaches to mitigate underlying metabolic dysregulation. Incretin-based therapies are emerging as a viable prospect to fulfil this unmet niche.
Harendran Elangovan, Rohit Loomba, Mark Muthiah, Jörn Schattenberg, Ming Hua Zheng, Mazen Noureddin, Christos Mantzoros, Jacob George   +7 more
doaj   +1 more source